Researchers detected a mutation in the GLA gene, which is defective in Fabry disease patients, in people with…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Pregnancy increased the severity and frequency of pain among women with Fabry disease who lived with moderate pain before…
Centogene has extended a collaboration deal with Takeda in which the two companies will continue to provide diagnostic…
Measures of heart function improved one to two years after treatment with 4D-310, an investigational gene therapy for Fabry…
Elfabrio (pegunigalsidase alfa) is as safe and effective as Fabrazyme (agalsidase beta) and can prevent kidney decline in adults…
4D Molecular Therapeutics (4DMT) has reached an agreement with the U.S. Food and Drug Administration (FDA) to lift the…
A review study revealed that those with Fabry disease have a high prevalence of a wide range of sleep…
Messenger RNA (mRNA) treatment restored levels of Gal A enzyme activity in heart cells derived from two Fabry disease…
More than half of adults with Fabry disease were found to have heart involvement that put them at risk…
Changes in the blood vessels within the eyes of people with Fabry disease may act as reliable, noninvasive biomarkers…